Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114854 · ClinicalTrials.gov registry record · Phase 1
A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)
A Phase 1 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT01114854 is a Phase 1 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 69 participants.
The verdict
NCT01114854, a Phase 1 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This multi-center, two-treatment study compares the pharmacokinetic profiles of Immediate Release (IR) and Modified Release (MR) formulations of Topiramate (TPM) in patients with epilepsy.
Interventions
- DRUG Topiramate IR
- DRUG Topiramate ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114854
The ClinicalTrials.gov registry entry for NCT01114854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topiramate IR is the first listed.
NCT01114854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01114854 about?
NCT01114854 is a clinical study titled "A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)". This multi-center, two-treatment study compares the pharmacokinetic profiles of Immediate Release (IR) and Modified Release (MR) formulations of Topiramate (TPM) in patients with epilepsy.
What is the current status of trial NCT01114854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2010-06. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01114854?
The interventions under investigation include: Topiramate IR (DRUG), Topiramate ER (DRUG).
Who is sponsoring clinical trial NCT01114854?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.